Wutah pendapatan taun lumaku: Cardiff Oncology, Inc. (CRDF)

The implementation of robotic systems for cellular screening accelerates therapy development, impacting the last twelve months (LTM) sales volume trend and daily price action on the GURU.Markets chart for Cardiff Oncology, Inc. (CRDF). The innovative PLK1 inhibitor provides pricing power, while the demand for onvansertib ensures a stable cash generator. The current value of 11.40 determines this specific level of the revenue growth parameter.
Cardiff Oncology - rincian analitis lan metrik utama (CRDF)

For the biotechnology sector, where Cardiff Oncology, Inc. (CRDF) focuses on the development of onvansertib, revenue dynamics serve as an indicator of commercialization and the ability to overcome cancer therapeutic resistance. The year-over-year sales growth percentage for the TTM on the GURU.Markets platform, equal to 11.40, is calculated as the change in total income over the last 12 months relative to the same period last year, reflecting the business's fundamental resilience to market shocks.